Clearstone Expands Testing Capabilities at Laboratory in Toronto
Clearstone Central Laboratories, a global provider of clinical laboratory and centralized cardiac services for clinical trials, announced the expansion of testing capabilities at its Toronto laboratory. Additional safety as well as esoteric testing capacity and capabilities will be added to the existing operations.
"Since the acquisition of this business from MDS Pharma Services last year we have set about improving every aspect of Clearstone's operation and service delivery," said Clearstone CEO Lewis Cameron. "We want Clearstone to be widely recognized as a leader and trusted service provider, committed to long term relationships, operating in an open and transparent way and offering expert, high quality and responsive service to all our clients. This purpose demands renewed investment in people, processes, systems, and infrastructure. The Toronto expansion is one example of our strategic plan and path forward, and we look forward to speaking with clients about these exciting developments.''
Clearstone CSO Dr. Patrice Hugo added, "The Toronto expansion follows recent investment and expansion at our Beijing site, with particular focus on enhancing our capabilities in flow cytometry and molecular biology. This expansion does result in some duplication of capabilities between our North American laboratories, and as such the laboratory operations at our New Jersey facility will be winding down over a six month period, with any remaining studies to be transitioned to the Toronto laboratory.''
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
